- Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trialLi, Ning; Zhu, Jianqing; Yin, Rutie; Wang, Jing; Pan, Lingya; Kong, Beihua; Zheng, Hong; Liu, Jihong; Wu, Xiaohua; Wang, Li; Huang, Yi; Wang, Ke; Zou, Dongling; Zhao, Hongqin; Wang, Chunyan; Lu, Weiguo; Lin, An; Lou, Ge; Li, Guiling; Qu, Pengpeng; Yang, Hongying; Zhen, Xiaoa; Hang, Wenzhao; Hou, Jianmei; Wu, Lingying被引 21
- Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trialLi, Ning; Zhu, Jianqing; Yin, Rutie; Wang, Jing; Pan, Lingya; Kong, Beihua; Zheng, Hong; Liu, Jihong; Wu, Xiaohua; Wang, Li; Huang, Yi; Wang, Ke; Zou, Dongling; Zhao, Hongqin; Wang, Chunyan; Lu, Weiguo; Lin, An; Lou, Ge; Li, Guiling; Qu, Pengpeng; Yang, Hongying; Zhen, Xiaoa; Hang, Wenzhao; Hou, Jianmei; Banerjee, Ashish; Wu, Lingying
- SABRINA study: A phase II study of senaparib monotherapy for patients (pts) with BRCA1/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC)Wu, X.; Liu, J.; Wang, L.; Lin, Z.; Wang, J.; Wang, C.; Kong, B.; Liang, Z.; Cheng, Y.; Wen, H.; Lou, G.; Huang, Y.; Wang, K.; An, R.; Zhu, J.; Zhou, H.; Yue, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
会议论文
Efficacy and safety of senaparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer (FLAMES study): A randomized, double-blind, placebocontrolled, phase III trial
6阅读
